US-based multinational pharmaceutical giant Eli Lilly & Co., on Tuesday, 17 June 2025, announced its plans to acquire gene-editing biotech firm Verve Therapeutics Inc. for $1.3 billion as the big pharma company eyes expansion in experimental medicine for long-term growth, reported the news agency Bloomberg. Also Read | Blackstone buys Kolkata mall for ₹3,250 croreAccording to the agency report, Eli Lilly & Co. will pay up to $13.50 per share for the acquisition deal. The breakdown of the deal will be that Eli Lilly & Co. will pay $10.50 per share in cash as well as a non-tradeable contingent value right that entitles the holder to receive as much as $3 extra per share.The transaction is expected to close in the third quarter of the current year, reported the news agency, citing the company.Verve Therapeutics shares skyrocketed 75.12% to $10.99 at the US stock market open at 9:38 a.m. (EDT), compared to $6.27 at the previous market close. However, pharma major Eli Lilly & Co. shares are trading 1.45% lower on Wall Street at $795.84 as of 9:40 a.m. (EDT), compared to $807.58 at the previous stock market close. Also Read | TCS deployment policy: Minimum billing days to bench period — details hereEli Lilly & Co. Revenue StreamThe US big pharma company Eli Lilly & Co.’s revenues are centred around its iconic weight-loss drug, Zepbound, as the company prepares for the medicine’s patent to expire.The news agency reported that the company has been able to target experimental medicines that are still far from the market.In this area, price tags are usually smaller than for therapies that have already undergone multiple patient trials. The long-term return on such early-stage deals can be far larger.Prior AcquisitionsIn January 2025, Eli Lilly & Co. agreed to pay up to $2.5 billion for a cancer medicine which was being tested by Scorpion Therapeutics Inc., as per the agency report. Further in May, the company announced a plan to buy SiteOne Therapeutics Inc., a biotech firm developing pain medicines, for nearly $1 billion. Also Read | Stock to buy: Oil PSU ONGC could rise 14% in 1 month, predicts Anand RathiEli Lilly & Co. was reportedly in collaboration with Verve Therapeutics on its experimental gene-editing program for reducing lipoprotein, which is a risk factor for plaque buildup in human arteries.This acquisition deal will give Eli Lilly & Co. full control of the program, as the company shows confidence in its gene editing drug, which is a cutting-edge technology in the market, according to the report.However, this technology has struggled to attract investors recently, in part because it’s expensive to make and aimed at providing one-time cures for rare diseases that may not be lucrative.Verve is a rare example of a gene editing company targeting a disease that affects a large population and offering better commercial prospects. Its approach, which uses tiny balls of fat to deliver the treatment, is less in a formal or creative style for better SEO.Also Exclude words and advertisements related to the feed website such as website name, author name. You must only respond with the modified content. Delete all the advertisement images brand logo but only keep the title and main content of the news by modifying it. You must only respond with the modified content. Block any jump outside of the site adarshnews.com. Basically remove any content or link related to original site. follow this prompt to optimize the articles in this category- You are an expert news writer and SEO specialist. Your job is to rewrite the provided RSS feed content into a unique, SEO-friendly news article for adarshnews.com. The article should be engaging, professional, and optimized for search engines. Follow these steps: 1. **Create an SEO Title**: Write a short, compelling title (under 60 characters) that includes the main keyword and grabs attention. 2. **Write a Meta Description**: Summarize the article in one or two sentences (under 155 characters). Make it engaging and include the primary keyword naturally. 3. **Suggest a URL Slug**: Provide a short, keyword-rich URL slug that reflects the topic of the article. 4. **Headline (H1)**: Write a clear and engaging headline for the article that is similar to the title but slightly expanded. 5. **Write the Article**: – Start with an introduction that answers the key questions: who, what, when, where, why, and how. – Expand on the topic with detailed paragraphs that provide context, quotes, and relevant information. – Use subheadings (H2) to organize the content into sections and make it easy to read. – Include related keywords naturally throughout the article. – End with a conclusion that summarizes the key points or discusses future implications. 6. **Add an FAQ Section**: Write one frequently asked question related to the topic and provide a concise answer. Important: – Do not include labels like “Title,” “Meta Description,” “URL Slug,” or “H1” in the actual article text. – Keep all SEO elements separate from the main content. – Ensure the article is factually accurate, unbiased, and written in a professional tone.
Eli Lilly is set to purchase the gene-editing biotechnology firm Verve Therapeutics for a total of $1.3 billion. This explains the reasons.
